Search Result

Results for "

Cynomolgus monkeys

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Btk (1) c-Met/HGFR (1) Cathepsin (2) Complement System (1) CXCR (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) EGFR (1) GCGR (2) GnRH Receptor (2) Histamine Receptor (2) HIV (2) HIV Integrase (1) Interleukin Related (5) mAChR (1) Melanocortin Receptor (1) Monoamine Oxidase (1) Orexin Receptor (OX Receptor) (1) P-selectin (1) Renin (1) Ser/Thr Protease (1) Sodium Channel (2) Tau Protein (1) Topoisomerase (1) Trace Amine-associated Receptor (TAAR) (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (9) Metabolic Disease (7) Neurological Disease (8)

By Targets:

11β-HSD (1)

Btk (1)

c-Met/HGFR (1)

Cathepsin (2)

Complement System (1)

CXCR (1)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (1)

EGFR (1)

GCGR (2)

GnRH Receptor (2)

Histamine Receptor (2)

HIV (2)

HIV Integrase (1)

Interleukin Related (5)

mAChR (1)

Melanocortin Receptor (1)

Monoamine Oxidase (1)

Orexin Receptor (OX Receptor) (1)

P-selectin (1)

Renin (1)

Ser/Thr Protease (1)

Sodium Channel (2)

Tau Protein (1)

Topoisomerase (1)

Trace Amine-associated Receptor (TAAR) (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (9)

Metabolic Disease (7)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109114

Dersimelagon MT-7117	Melanocortin Receptor	Metabolic Disease
Dersimelagon (MT-7117) is an orally active, selective melanocortin 1 receptor (MC1R) agonist with EC₅₀ values of 8.16, 3.91, 1.14 and 0.251 nM for human (h), cynomolgus monkey (cm), mouse (m) and rat (r) MC1R, respectively. Dersimelagon shows good affinity for hMC1R and hMC4R with K_i values of 2.26, 32.9 nM, respectively. Dersimelagon can be used for the research of skin pigmentation .

HY-10198

Navarixin Maximum Cited Publications 19 Publications Verification SCH 527123; MK-7123	CXCR	Inflammation/Immunology Endocrinology Cancer
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with K_d values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly .

HY-12699

RO5166017 1 Publications Verification	Trace Amine-associated Receptor (TAAR)	Metabolic Disease
RO5166017 is an orally active and species-crosses TAAR1 agonist, with K_i values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively .

HY-112209

VU0467154 1 Publications Verification	mAChR	Neurological Disease
VU0467154 is a positive allosteric modulator of the M4 muscarinic acetylcholine receptor (mAChR), potentiating the response to ACh with pEC₅₀s of 7.75, 6.2 and 6 for rat, human and cynomolgus monkey M4 receptor, respectively.

HY-112583

MIV-247

Cathepsin Neurological Disease

MIV-247 is a selective cathepsin S inhibitor with K_is of 2.1, 4.2 and 7.5 nM for human, mouse and cynomolgus monkey cathepsin S, respectively.

MIV-247	Cathepsin	Neurological Disease
MIV-247 is a selective cathepsin S inhibitor with K_is of 2.1, 4.2 and 7.5 nM for human, mouse and cynomolgus monkey cathepsin S, respectively.

HY-P99439

Anrukinzumab IMA-638	Interleukin Related	Inflammation/Immunology
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .

HY-130249

BAY-298	GnRH Receptor	Endocrinology
BAY-298 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC₅₀s of 96 nM, 23 nM and 78 nM for hLH (human LH) and rLH (rat LH) and cLH (cynomolgus monkey LH), respectively. BAY-298 can reduce sex hormone levels .

HY-101930B

(R)-BMS-816336	11β-HSD	Metabolic Disease
(R)-BMS-816336 (Compound 6n-1) is a potent and orally active inhibitor of human, mouse and cynomolgus monkey 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC₅₀s of 14.5 nM, 50.3 nM and 16 nM, respectively .

HY-112185

Orforglipron LY3502970; GLP-1 receptor agonist 1	GCGR	Metabolic Disease
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .

HY-112185A

Orforglipron hemicalcium hydrate LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate	GCGR	Metabolic Disease
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .

HY-P990093

Stapokibart CM310	Interleukin Related	Inflammation/Immunology
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .

HY-12811

PF-04856264	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective Nav1.7 inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .

HY-P9931

Guselkumab CNTO 1959	Interleukin Related	Inflammation/Immunology
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with K_d values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .

HY-P99248

Risankizumab Risankizumab rzaa; BI 655066	Interleukin Related	Inflammation/Immunology
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K_d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC₅₀ = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .

HY-P0013

Antide

D-21074; ORF 23541
GnRH Receptor Cancer

Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

HY-P99786

Pozelimab REGN3918	Complement System	Metabolic Disease
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .

HY-10294

Relacatib SB-462795	Cathepsin	Metabolic Disease Cancer
Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with K_i values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC₅₀ values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .

HY-16785

Veledimex INXN-1001; RG-115932	Interleukin Related	Inflammation/Immunology Cancer
Veledimex (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system. Veledimex can be used to activate certain genes using the ecdysone receptor (EcR)-based inducible gene regulation system, the RheoSwitch Therapeutic System (RTS). Veledimex can cross blood-brain barrier (BBB) in both orthotopic GL-261 mice and cynomolgus monkeys .

HY-P99399

Semorinemab RG 6100; RO7105705; MTAU-9937A	Tau Protein	Neurological Disease
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a K_d value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .

HY-157802

LTGO-33	Sodium Channel	Neurological Disease
LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .

HY-P99584

Suvizumab KD-247	HIV	Infection
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1_MN, HIV-1_SF2 and HIV-1_89.6 with IC₅₀ values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P99110

Lanadelumab SHP643; DX-2930	Ser/Thr Protease	Inflammation/Immunology
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an K_i value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .

HY-150080

GSK3739936 BMS-986180	HIV HIV Integrase	Infection
GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC₅₀ value of 11.1 nM and an EC₅₀ value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC₅₀>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability .

HY-105276

Enalkiren A-64662	Renin	Cardiovascular Disease
Enalkiren (A-64662) is a potent dipeptide renin inhibitor with an IC₅₀ of 0.78 nM in a purified renal renin-angiotensinogen system (pH=6.0). Enalkiren suppresses renin activity, and also reduces systolic and diastolic blood pressure. Enalkiren can be used to research essential hypertension .

HY-P99250

Onartuzumab MetMAb	c-Met/HGFR	Cancer
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .

HY-P99836

Cudarolimab IBI101	Orexin Receptor (OX Receptor)	Inflammation/Immunology Cancer
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .

HY-153360

MC-GGFG-AM-(10Me-11F-Camptothecin)	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .

HY-P99263

Inclacumab Anti-Human selectin P Recombinant Antibody	P-selectin	Cardiovascular Disease
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a K_d value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC₅₀ value of 1.9 μg/mL and strongly inhibits cell adhesion .

HY-148130

Rugonersen RG6091; RO7248824	E1/E2/E3 Enzyme	Others
Rugonersen (RG6091; RO7248824) is a locked-nucleic acid (LNA)- modified antisense oligonucleotides (ASOs), and results in reduction of ubiquitin-protein ligase E3A (UBE3A) silencing. Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, Rugonersen has been used for AS reasearch .

HY-109968A

Irdabisant hydrochloride CEP-26401 hydrochloride	Histamine Receptor	Neurological Disease
Irdabisant (CEP-26401) hydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with K_i values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant hydrochloride has relatively low inhibitory activity against hERG current with an IC₅₀ of 13.8 μM. Irdabisant hydrochloride has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant hydrochloride can be used to research schizophrenia or cognitive impairment .

HY-109968

Irdabisant CEP-26401	Histamine Receptor	Neurological Disease
Irdabisant (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with K_i values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant has relatively low inhibitory activity against hERG current with an IC₅₀ of 13.8 μM. Irdabisant has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used to research schizophrenia or cognitive impairment .

HY-115987

MAO-B-IN-6	Monoamine Oxidase	Neurological Disease
MAO-B-IN-6 is a potent, selective and orally active MAO-B inhibitor with an IC₅₀ of 0.019 µM. MAO-B-IN-6 shows more efficacious than Safinamide in vitro and in vivo. MAO-B-IN-6 has the potential for the research of parkinson's disease (PD) .

HY-153220

NX-2127	Btk	Cancer
NX-2127 is an orally and potent BTK inhibitor, inducing degradation of the mutated BTK ^C481S in cells. NX-2127 inhibits proliferation of BTK ^C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells .

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

Cat. No.	Product Name	Target	Research Area